Vistagen Investors Urged to Discuss Legal Rights Amid Significant Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VTGN?
Source: PRnewswire
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased or acquired securities between April 1, 2024, and December 16, 2025, indicating significant legal exposure for the company.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the legal risks that could adversely affect the company's stock price.
- Contact Information Provided: Investors wishing to discuss their legal rights can directly contact Faruqi & Faruqi partner Josh Wilson, with multiple contact numbers provided to facilitate investor inquiries.
- Market Reaction Anticipation: Given the potential impact of the legal proceedings, Vistagen's stock price may face further downward pressure, necessitating investors to closely monitor developments to safeguard their interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.610
Low
0.90
Averages
0.97
High
1.00
Current: 0.610
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vistagen Investors Urged to Discuss Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased or acquired securities between April 1, 2024, and December 16, 2025, indicating significant legal exposure for the company.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the legal risks that could adversely affect the company's stock price.
- Contact Information Provided: Investors wishing to discuss their legal rights can directly contact Faruqi & Faruqi partner Josh Wilson, with multiple contact numbers provided to facilitate investor inquiries.
- Market Reaction Anticipation: Given the potential impact of the legal proceedings, Vistagen's stock price may face further downward pressure, necessitating investors to closely monitor developments to safeguard their interests.
See More
Vistagen Therapeutics Investor Claim Notice
- Investor Claim Notice: Levi & Korsinsky LLP is urging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to contact them before the lead plaintiff deadline, highlighting the firm's commitment to protecting investor rights.
- Clinical Trial Progress: On April 1, 2024, Vistagen announced the enrollment of the first patient in its PALISADE-3 Phase 3 trial, with management describing this as a significant milestone in the development and commercialization of the drug candidate, indicating proactive advancements in R&D.
- Fiscal Year Performance and Enhancements: The fiscal year 2024 results revealed that COO Joshua Prince discussed notable enhancements, including in-person investigator meetings and rigorous site training, aimed at optimizing trial quality, which is crucial for the credibility of clinical outcomes.
- Trial Results Disclosure: On December 17, 2025, the company disclosed that the Phase 3 study did not show statistically significant improvement on the primary endpoint, with management characterizing the results as unexpected, potentially undermining investor confidence and raising concerns about the drug's viability.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging securities fraud and unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by March 16, 2026, indicating significant legal risks for the firm.
- Stock Price Plunge: Following the announcement on December 17, 2025, that the PALISADE-3 study failed to meet its primary endpoint, Vistagen's stock price plummeted by 80.25% to close at $0.861 per share, reflecting extreme market pessimism regarding the company's future prospects.
- Study Results Impact: The trial did not demonstrate a statistically significant improvement for fasedienol in treating social anxiety disorder, failing to show treatment differences from placebo on both primary and secondary endpoints, exacerbating investor concerns about the company's product pipeline.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in corporate and securities class litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise and influence in handling such cases.
See More
Faruqi & Faruqi Investigates Vistagen Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Vistagen Therapeutics for potentially misleading investors regarding the PALISADE-3 clinical trial, which may have led to significant financial losses due to inflated stock prices.
- Stock Price Plummet: On December 17, 2025, Vistagen announced that its PALISADE-3 study failed to meet its primary efficacy endpoint, resulting in an over 81% drop in stock price to $0.88 per share, severely undermining investor confidence.
- Class Action Reminder: Investors are reminded to apply by March 16, 2026, to serve as lead plaintiffs in the federal securities class action against Vistagen, with Faruqi & Faruqi offering legal support to protect investor rights.
- Information Solicitation: Faruqi & Faruqi encourages anyone with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward to assist in the ongoing legal investigation, assuring that all communications will be kept confidential.
See More
Vistagen Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Vistagen Therapeutics for violations of securities laws, concerning trades made between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026, to participate.
- False Statements Allegation: The complaint alleges that Vistagen misled investors regarding the likelihood of success for its fasedienol drug candidate by falsely portraying positive results from the PALISADE-2 trial, thereby downplaying the risks of clinical study failures and causing investor losses.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action may remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out for discussions about their rights, emphasizing the availability and importance of legal assistance in such matters.
See More
Vistagen Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiffs by March 16, 2026, to participate in the class action and seek compensation.
- Fee Structure: Investors joining the Vistagen class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby alleviating financial burdens on investors.
- Case Background: The lawsuit alleges that Vistagen misled investors by issuing overly optimistic statements regarding its drug fasedienol's development while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
See More
Vistagen Investors Urged to Discuss Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased or acquired securities between April 1, 2024, and December 16, 2025, indicating significant legal exposure for the company.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the legal risks that could adversely affect the company's stock price.
- Contact Information Provided: Investors wishing to discuss their legal rights can directly contact Faruqi & Faruqi partner Josh Wilson, with multiple contact numbers provided to facilitate investor inquiries.
- Market Reaction Anticipation: Given the potential impact of the legal proceedings, Vistagen's stock price may face further downward pressure, necessitating investors to closely monitor developments to safeguard their interests.
See More
Vistagen Therapeutics Investor Claim Notice
- Investor Claim Notice: Levi & Korsinsky LLP is urging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to contact them before the lead plaintiff deadline, highlighting the firm's commitment to protecting investor rights.
- Clinical Trial Progress: On April 1, 2024, Vistagen announced the enrollment of the first patient in its PALISADE-3 Phase 3 trial, with management describing this as a significant milestone in the development and commercialization of the drug candidate, indicating proactive advancements in R&D.
- Fiscal Year Performance and Enhancements: The fiscal year 2024 results revealed that COO Joshua Prince discussed notable enhancements, including in-person investigator meetings and rigorous site training, aimed at optimizing trial quality, which is crucial for the credibility of clinical outcomes.
- Trial Results Disclosure: On December 17, 2025, the company disclosed that the Phase 3 study did not show statistically significant improvement on the primary endpoint, with management characterizing the results as unexpected, potentially undermining investor confidence and raising concerns about the drug's viability.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Vistagen Therapeutics, alleging securities fraud and unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by March 16, 2026, indicating significant legal risks for the firm.
- Stock Price Plunge: Following the announcement on December 17, 2025, that the PALISADE-3 study failed to meet its primary endpoint, Vistagen's stock price plummeted by 80.25% to close at $0.861 per share, reflecting extreme market pessimism regarding the company's future prospects.
- Study Results Impact: The trial did not demonstrate a statistically significant improvement for fasedienol in treating social anxiety disorder, failing to show treatment differences from placebo on both primary and secondary endpoints, exacerbating investor concerns about the company's product pipeline.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in corporate and securities class litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its expertise and influence in handling such cases.
See More
Faruqi & Faruqi Investigates Vistagen Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Vistagen Therapeutics for potentially misleading investors regarding the PALISADE-3 clinical trial, which may have led to significant financial losses due to inflated stock prices.
- Stock Price Plummet: On December 17, 2025, Vistagen announced that its PALISADE-3 study failed to meet its primary efficacy endpoint, resulting in an over 81% drop in stock price to $0.88 per share, severely undermining investor confidence.
- Class Action Reminder: Investors are reminded to apply by March 16, 2026, to serve as lead plaintiffs in the federal securities class action against Vistagen, with Faruqi & Faruqi offering legal support to protect investor rights.
- Information Solicitation: Faruqi & Faruqi encourages anyone with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward to assist in the ongoing legal investigation, assuring that all communications will be kept confidential.
See More
Vistagen Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Vistagen Therapeutics for violations of securities laws, concerning trades made between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026, to participate.
- False Statements Allegation: The complaint alleges that Vistagen misled investors regarding the likelihood of success for its fasedienol drug candidate by falsely portraying positive results from the PALISADE-2 trial, thereby downplaying the risks of clinical study failures and causing investor losses.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action may remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out for discussions about their rights, emphasizing the availability and importance of legal assistance in such matters.
See More
Vistagen Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiffs by March 16, 2026, to participate in the class action and seek compensation.
- Fee Structure: Investors joining the Vistagen class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby alleviating financial burdens on investors.
- Case Background: The lawsuit alleges that Vistagen misled investors by issuing overly optimistic statements regarding its drug fasedienol's development while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and successful track record in this field.
See More
